Samsung Bioepis released its first US Biosimilar Market Report which found that biosimilars will save the US healthcare system $181B in the next five years. The report will be published each quarter after the Center of Medicare, Medicaid Services publishes new data. Key findings from the report include:
- On average, biosimilars gained 53% market share in the three years after their initial launch. This was influenced by the faster acceptance (75%) for oncology compared to other therapeutic areas (25%) and for pegfilgrastim compared to other molecules
- Average sales prices declined 41% on average three years after first biosimilar launch. The prices for oncology biosimilars experienced the steepest decline (each dropping >50% in the first three years after biosimilar launch)
- Unbranded insulin glargines are discounted by up to 66% compared to Lantus® (Sanofi)
- As of Q4 2022 the biosimilar share of the trastuzumab market has reached 82%